Pre-made Bifikafusp benchmark antibody ( Whole mAb Fusion, anti-FN extra domain B therapeutic antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-068
Anti-FN extra domain B therapeutic antibody (Pre-made Bifikafusp biosimilar,Whole mAb Fusion) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Anti-FN extra domain B therapeutic antibody (Pre-made Bifikafusp biosimilar,Whole mAb Fusion)|
|Target||FN extra domain B|
|Format||Whole mAb Fusion|
|Highest_Clin_Trial (Jan '20)||Phase-III|
|100% SI Structure||None|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Conditions Active||Non-small cell lung cancer;Diffuse large B-cell lymphoma;[With onfekafusp] Malignant melanoma;[With onfekafusp] Basal cell cancer;[With onfekafusp] Squamous cell cancer;[With onfekafusp] Solid tumours|
|Conditions Discontinued||Malignant melanoma;Renal cell carcinoma;Solid tumours;Atherosclerosis;Head and neck cancer;Pancreatic cancer|